FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression By Ogkologos - June 13, 2025 574 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LUMINOSITY study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR For Older Adults, Geriatric Assessment Reduces Cancer Treatment Side Effects December 15, 2021 Is CBD Safe for People With Cancer? September 22, 2020 Meeting Cancer Survivors’ Psychosocial Health Needs: A Conversation with Dr. Patricia... June 7, 2022 Foodie Friday: Watermelon Fruit Pizza September 3, 2021 Load more HOT NEWS An Important Part of Cancer Caregiving That’s Often Overlooked and How... 5 ways cancer can impact sexual wellbeing Limited Efficacy of Nivolumab plus Ipilimumab in Adenoid Cystic Carcinomas, but... How People With Cancer Can Make the Most of Televisits
